McMaster University in Canada has inked a research deal with MYOS RENS Technology (MYOS) to examine the impact of Fortetropin® on reducing muscle disuse atrophy in young men.
A randomized, placebo-controlled clinical trial, 24 male participants will consume Fortetropin or a macronutrient-matched placebo for 6 weeks. After a 2-week Fortetropin pre-treatment phase, participants will wear a knee brace for 2 weeks in order to stimulate immobilization-induced muscle disuse atrophy. Thereafter, the knee brace will be removed while the participant continues to take Fortetropin for an additional 2 weeks known as the recovery phase. The study will examine the impact of Fortetropin on reducing muscle disuse atrophy in young men. Muscle atrophy due to disuse commonly occurs in response to immobilization, such as the atrophy of the thigh muscles following a period of casting for fracture or following surgery such as knee replacement.
What is Fortetropin®
Fortetropin is a proprietary bioactive composition made from fertilized egg yolk that helps bring lean muscle. Fortetropin is a natural food product made from fertilized hen egg yolks that has been shown to minimize disuse atrophy in the thigh muscles of dogs that had undergone leg ligament repair surgery.
Who makes Fortretropin?
MYO RENS Technology (MYOS)
What is MYO RENS Technology Background?
MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional and therapeutic products that enhance muscle health and performance. The company primarily focuses on developing products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Qurr line of products comprising flavored puddings, powders, and shakes; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform; and at the Vitamin Shoppe. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery development and commercialization of products that improve muscle health and performance; and Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
What is MYO RENS Technology Financial Status?
A micro-cap venture, their stock trades presently at $1.44. Their total market capitalization is $13.7 million. Revenues is about $520K and they have a projected loss of about $.3.7 million. They hold about $1.16 million. They are heavily owned by insiders. They currently employ about 15 based on TrialSite News estimates.
Stuart M. Phillips, PhD, Professor of Kinesiology, Canada Research Chair and Director, Physical Activity Centre of Excellence (PACE) at McMaster University. Professor Phillips, a key opinion leader in the field of muscle physiology and sarcopenia with over 200 peer-reviewed publications and will oversee an interdisciplinary team of scientists and physicians for the trial.
Call to Action: Is the topic of interest? We will follow the study. We offer link to Dr. Phillips link as well.